Abeona Therapeutics

Abeona Therapeutics (NASDAQ: ABEO) is an early-stage biotechnology company focused on developing therapies for the deadly childhood genetic diseases Sanfilippo (SF) Syndrome Type A and Type B. The company’s two lead products, ABX-A and ABX-B, uniquely deliver the therapeutic product to the central nervous system with the aim of reversing the effects of the genetic errors that cause the disease.
Read the Case Study

Funding: Cure Sanfilippo Foundation, Sanfilippo Research Foundation (SRF), Team Sanfilippo, Abby Grace Foundation, National MPS Society, Stop Sanfilippo and Sanfilippo B Foundation (Spain), Foundation Sanfilippo (Switzerland), Red Sanfilippo Foundation (Mexico), Soros Fund Management, Perspective Life Science Fund

Stage: Clinical

News: Abeona Granted Licenses to Develop Gene Therapies for Four Rare Disorders